Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Cytokinetics, IncorporatedNASDAQ: CYTK
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures grows, but more slowly than its trailing trend
Q2 FY2026 capital expenditures of $4.33M (cash outflow) rose 4.6% year over year, behind the +86.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 26.9% from the prior quarter. Over 3 fiscal years it compounded at +29.8% a year.
Context
- Capital expenditures amounted to 28.2% of revenue in FY2025, up 7.0 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +4.6% toward the trailing-twelve-month pace of +86.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (24.81M) USD
- Year-over-year change
- -535.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (24.81M) | -535.1% |
| FY2024 | 2024-12-31 | (3.91M) | -175.8% |
| FY2023 | 2023-12-31 | (1.42M) | +87.5% |
| FY2022 | 2022-12-31 | (11.34M) | +76.8% |
| FY2021 | 2021-12-31 | (48.87M) | — |
Capital Expenditures vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's LTM Jun 2026 capital expenditures of $25.26M is the largest of the 3 companies compared; the peer median is $845.5K.
- Its year-over-year change of +86.4% is the highest of 2, against a peer median of -70.9%.
- Capital expenditures amounts to 35.6% of revenue for CYTK, versus a peer median of 58.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $25.26M | +86.4% | +29.8% | 35.6% | |
| FY2025 | $1.45M | — | — | 7.8% | |
| LTM Mar 2026 | $246K | -70.9% | -68.9% | 109.3% | |
| — | — | — | — | — | |
| Peer median (excluding CYTK) | $845.5K | -70.9% | -68.9% | 58.5% | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Depreciation & Amortization | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| Deferred Income Tax | 2.84M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.83M | 47.85M | 72.07M | 97.84M | 112.29M |
| Change in Working Capital | 8.46M | (24.7M) | 3.09M | 35.66M | (35.63M) |
| Accounts Receivables | (47.4M) | 56.67M | (1.14M) | (15.37M) | (1.11M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.06M | 4.52M | (3.48M) | (4.48M) | 2.66M |
| Other Working Capital | 54.8M | (85.9M) | 7.71M | 55.51M | (37.18M) |
| Other Non-Cash Items | 32.38M | 60.48M | 24.87M | 50.6M | 188.16M |
| Operating Cash Flow | (142.52M) | (299.52M) | (414.33M) | (395.89M) | (510.01M) |
| Capital Expenditures | (48.87M) | (11.34M) | (1.42M) | (3.91M) | (24.81M) |
| Acquisitions (Net) | 98.91M | 250.8M | 0 | 0 | 0 |
| Purchases of Investments | (525.04M) | (855.39M) | (635.21M) | (1.29B) | (1.06B) |
| Sales of Investments | 426.14M | 604.59M | 875.88M | 744.23M | 1.11B |
| Other Investing Activities | (98.91M) | (250.8M) | 0 | 0 | (5M) |
| Investing Cash Flow | (147.78M) | (262.13M) | 239.25M | (553.1M) | 16.67M |
| Debt Repayment | 0 | 334.66M | (858K) | (9.62M) | 490.95M |
| Common Stock Issued | 312.05M | 17.54M | 164.23M | 706.84M | 35.98M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.93M | 163.96M | 57.94M | 233.39M | (2.47M) |
| Financing Cash Flow | 319.98M | 516.17M | 221.32M | 930.61M | 524.46M |
| Effect of Forex Changes | 0 | 0 | (20K) | 209K | (715K) |
| Net Change in Cash | 29.68M | (45.48M) | 46.22M | (18.17M) | 30.4M |
| Free Cash Flow | (191.39M) | (310.85M) | (415.75M) | (399.8M) | (534.82M) |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.